Clinical Trials

480 enrolled

Other solid neoplasm

Advanced Malignant Solid Tumors

NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

146 enrolled

Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

NCT07469956 2026-03-13

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

Phase 1/2 Not yet recruiting

Pancreatic Neoplasms

NCT07277322 2026-03-02

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

24 enrolled

Colorectal Neoplasms

NCT06952621 2026-01-30

TD-NEOE3V3

390 enrolled

Esophageal Squamous Cell Carcinoma

NCT07378306 2026-01-30

FACT-TN

80 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07376499 2026-01-29

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

31 enrolled

Small Cell Lung Carcinoma

NCT07371897 2026-01-28

SHINE

154 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07363330 2026-01-26

A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer

32 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

NCT07362186 2026-01-23

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

400 enrolled

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

120 enrolled

NSCLC

NCT07342322 2026-01-15

A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma

Phase 1 Not yet recruiting

25 enrolled

Sarcoma

NCT06283134 2026-01-07

A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

60 enrolled

Colorectal Neoplasms

NCT07279597 2025-12-19

A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer

45 enrolled

Genitourinary

Muscle-invasive Bladder Urothelial Carcinoma

NCT07286942 2025-12-16

Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial

24 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07272291 2025-12-09

A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma

48 enrolled

Esophageal Squamous Cell Carcinoma

NCT07256964 2025-12-02

Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer

216 enrolled

Triple Negative Breast Neoplasms

NCT07244874 2025-11-24

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

41 enrolled

Phase 1/2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07245901 2025-11-24

Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

60 enrolled

Other solid neoplasm

Solid Tumor

NCT07246330 2025-11-24

Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study

340 enrolled

Esophageal Squamous Cell Carcinoma

NCT07189793 2025-09-24

OHAI-NMIBC-01

106 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07177794 2025-09-17

EC-CRT-008

242 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

150 enrolled

Triple Negative Breast Neoplasms

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

65 enrolled

Biliary Tract Neoplasms

NCT07136519 2025-08-22

Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

NCT07110558 2025-08-07

PUPA

59 enrolled

Nasopharyngeal Carcinoma

NCT07101614 2025-08-03

A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

125 enrolled

Triple Negative Breast Neoplasms

NCT07097948 2025-08-01

Adjuvant

40 enrolled

Recurrence, Small Cell Lung Carcinoma

NCT06987123 2025-05-23

TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial

62 enrolled

Nasopharyngeal Carcinoma

NCT06861712 2025-04-25

Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer

50 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06873854 2025-03-13

A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Phase 1 Not yet recruiting

84 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06732258 2024-12-27

Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

12 enrolled

Small Cell Lung Carcinoma

NCT06751394 2024-12-27

TRACER

44 enrolled

Phase NA Not yet recruiting

Rectal Neoplasms

NCT06709274 2024-11-29

MOTION-NSCLC

342 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06692491 2024-11-18

SPRING

200 enrolled

Rare Tumour

NCT06647563 2024-10-18

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

355 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT06648200 2024-10-18

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

100 enrolled

Phase 1 Not yet recruiting

Recurrence, Small Cell Lung Carcinoma

NCT06389526 2024-09-19

A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors

48 enrolled

Tumor-Agnostic

Neoplasms

NCT06588335 2024-09-19

BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

20 enrolled

Esophageal Squamous Cell Carcinoma

NCT06548763 2024-08-12

Oral Topotecan With Toripalimab for Patients With Endometrial Cancer

Phase 1/2 Not yet recruiting

Gynecologic

Endometrial Neoplasms

NCT06370754 2024-04-17

FD-IMPACT

117 enrolled

Pancreatic Neoplasms

NCT05773079 2024-04-01

Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma

28 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06283121 2024-02-29

A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer

Neoplasm Metastasis, Stomach Neoplasms

NCT06080854 2023-10-12

AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer

108 enrolled

Pancreatic Neoplasms

NCT05996484 2023-08-21

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

25 enrolled

Esophageal Neoplasms

NCT05993858 2023-08-15

PC-1

33 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05962021 2023-08-01

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

126 enrolled

Non Squamous Non Small Cell Lung Cancer

NCT05970627 2023-08-01

Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Adenocarcinoma of the Stomach

NCT05891080 2023-06-06

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

124 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05791136 2023-03-30

TREE